Mixture preparation

A technology of mixtures and preparations, applied in the fields of addiction medicine and neurobiology, can solve the problems of inability to forget the pleasure of drugs, lack of self-control for drug withdrawal, etc., and achieve the effects of shortening withdrawal time, low cost, and small toxic and side effects

Inactive Publication Date: 2008-04-30
昆明艾迪康生物科技有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The pain brought by drugs to them is mainly divided into two parts. One is the withdrawal symptoms during the physiological withdrawal process. This process usually lasts for 10-15 days. Self-injury and self-mutilation behavior, in order to alleviate these pains, they relapse into drug use; the second is psychological withdrawal, they cannot forget the pleasure brought by drugs and lack the self-control of drug withdrawal, and desperately pursue that pleasure all their lives. This kind of madness doesn't work through education

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Select ergot-like dopamine (DA) receptor agonist bromocriptine mesilate (Bromocriptine Mesilate) and γ-aminobutyric acid A receptor (GABA A ) agonist indiplon (indiplon) crude drug, with different dosages to make corresponding dosage forms.

[0024] a. Powder: choose ergot dopamine (DA) receptor agonist bromocriptine mesilate (Bromocriptine Mesilate) bulk drug 0.001% and gamma-aminobutyric acid A receptor (GABA A ) agonist indiplon (indiplon) bulk drug 89.999%, auxiliary material 10%, adopt conventional process to make powder.

[0025] Dosage: Three times a day, one bag at a time; 5 days is a course of treatment.

[0026] b. Dropping pills: choose ergot dopamine (DA) receptor agonist bromocriptine mesilate (Bromocriptine Mesilate) crude drug 1.5% and gamma-aminobutyric acid A receptor (GABA A ) agonist indiplon (indiplon) crude drug 97.9%, auxiliary material is 0.6%, adopts conventional process to make drop pill.

[0027] Dosage: three times a day, 8 capsules each ti...

Embodiment 2

[0051] Select the ergot-like dopamine (DA) receptor agonist pergolide mesylate and the gamma-aminobutyric acid B receptor (GABA B ) agonist baclofen (Beclofen) crude drug, with different dosage preparation processes to make corresponding dosage forms.

[0052] a. Powder: choose ergot dopamine (DA) receptor agonist pergolide mesylate (Pergolide Mesylate) raw material 0.001% and gamma-aminobutyric acid A receptor (GABA A ) agonist baclofen (Beclofen) crude drug 89.999%, auxiliary material is 10%, adopts conventional process to make powder.

[0053] Dosage: Three times a day, one bag at a time; 5 days is a course of treatment.

[0054] b. Dropping pills: choose ergot dopamine (DA) receptor agonist pergolide mesylate (Pergolide Mesylate) raw material 1.5% and gamma-aminobutyric acid A receptor (GABA A ) agonist baclofen (Beclofen) crude drug 97.9%, auxiliary material is 0.6%, adopts conventional process to make drop pill.

[0055] Dosage: three times a day, 8 capsules each time...

Embodiment 3

[0080] Choice of ergot dopamine (DA) receptor agonist lisuride (Lisuride), gamma-aminobutyric acid A receptor (GABA A ) agonist Zolpidem (Zolpidem), and gaboxadol (gaboxadol) raw materials, prepared into corresponding dosage forms with different dosages.

[0081] a. Powder: select ergot dopamine (DA) receptor agonist lisuride (Lisuride) crude drug 0.001%, gamma-aminobutyric acid A receptor (GABA A ) agonist Zolpidem (Zolpidem) bulk drug 35%, gaboxadol (gaboxadol) bulk drug 54.999%, excipients 10%, using conventional technology to make powder.

[0082] Dosage: Three times a day, one bag at a time; 5 days is a course of treatment.

[0083] b. Dropping pills: select ergot dopamine (DA) receptor agonist lisuride (Lisuride) crude drug 1.5%, gamma-aminobutyric acid A receptor (GABA A ) agonist Zolpidem (Zolpidem) crude drug 26.325%, gaboxadol (gaboxadol) crude drug 71.575%, excipients 0.6%, using conventional technology to make drop pills.

[0084] Dosage: three times a day, 8 ca...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided is a combinative preparation, belonging to technical field of addiction medicines and neurobiology. The raw materials are receptor agonist raw medicine of ergot dopamine (DA), receptor agonist raw medicine of gamma-propalanine A receptor (GABAA), receptor agonist raw medicine of gamma-propalanine B receptor (GABAB) and excipients. The weight ratios of the raw materials are that the receptor agonist raw medicine of ergot dopamine (DA) is 0.0001% to 30%, the receptor agonist raw medicine of gamma-propalanine A receptor (GABAA) and the receptor agonist raw medicine of gamma- propalanine B receptor (GABAB) are 99.009% to 65%, and the excipients are the rest percentage. Pulvis, drop pills, micro-granules, suppositories, solution type injections, suspension type injections, emulsion type injections, asepsis powder for injection, solutions, syrups, emulsions, suspensions and controlled released preparations are produced by employing the conventional technology. The invention has the advantages of low costs, safety, reliability, little toxic and side effects, obvious shortening of withdrawal time, obvious alleviation or partially relief of psychological drug craving and the like, being adaptable to detoxification medicines for curing various drug addictions.

Description

Technical field: [0001] The invention relates to a mixture preparation and belongs to the technical fields of addiction medicine and neurobiology. Background technique: [0002] my country currently has more than 1.17 million registered drug addicts. According to the 1:10 ratio of registered drug addicts to drug addicts recommended by the United Nations anti-drug agency, the number of drug addicts in my country has exceeded 11 million. The existence of this special group seriously threatens the social stability and sustainable development of our country. The drug problem has become a national construction The main threat to a harmonious society. In order to win the fight against drug addiction, we must rely on biomedical technology for drug addiction withdrawal. Strengthening the pace of R&D and application in this technology field plays an important role in achieving breakthroughs in drug control work in a relatively short period of time. [0003] At present, all countries...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K45/00A61K31/4985A61K31/48A61K9/02A61K9/08A61K9/10A61K9/107A61K9/14A61P25/36A61K31/195A61K31/437A61K31/4184
Inventor 刘正琴陈贵超
Owner 昆明艾迪康生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap